239 related articles for article (PubMed ID: 26503641)
1. A phosphodiesterase 4B-dependent interplay between tumor cells and the microenvironment regulates angiogenesis in B-cell lymphoma.
Suhasini AN; Wang L; Holder KN; Lin AP; Bhatnagar H; Kim SW; Moritz AW; Aguiar RCT
Leukemia; 2016 Mar; 30(3):617-626. PubMed ID: 26503641
[TBL] [Abstract][Full Text] [Related]
2. The phosphodiesterase PDE4B limits cAMP-associated PI3K/AKT-dependent apoptosis in diffuse large B-cell lymphoma.
Smith PG; Wang F; Wilkinson KN; Savage KJ; Klein U; Neuberg DS; Bollag G; Shipp MA; Aguiar RC
Blood; 2005 Jan; 105(1):308-16. PubMed ID: 15331441
[TBL] [Abstract][Full Text] [Related]
3. Phosphodiesterase 4B is an effective therapeutic target in colorectal cancer.
Kim DU; Kwak B; Kim SW
Biochem Biophys Res Commun; 2019 Jan; 508(3):825-831. PubMed ID: 30528730
[TBL] [Abstract][Full Text] [Related]
4. Disruption of the Myc-PDE4B regulatory circuitry impairs B-cell lymphoma survival.
Nam J; Kim DU; Kim E; Kwak B; Ko MJ; Oh AY; Park BJ; Kim YW; Kim A; Sun H; Jung Y; Lee JH; Shin HJ; Park I; Song DK; Jeong JY; Lee YH; Kim SW
Leukemia; 2019 Dec; 33(12):2912-2923. PubMed ID: 31138843
[TBL] [Abstract][Full Text] [Related]
5. Cyclic-AMP signalling, MYC and hypoxia-inducible factor 1α intersect to regulate angiogenesis in B-cell lymphoma.
Ethiraj P; Sasi B; Holder KN; Lin AP; Qiu Z; Jaafar C; Elkhalili A; Desai P; Saksena A; Ritter JP; Aguiar RCT
Br J Haematol; 2022 Jul; 198(2):349-359. PubMed ID: 35411936
[TBL] [Abstract][Full Text] [Related]
6. Gene set enrichment analysis unveils the mechanism for the phosphodiesterase 4B control of glucocorticoid response in B-cell lymphoma.
Kim SW; Rai D; Aguiar RC
Clin Cancer Res; 2011 Nov; 17(21):6723-32. PubMed ID: 21742807
[TBL] [Abstract][Full Text] [Related]
7. Synergistic Targeting of the Regulatory and Catalytic Subunits of PI3Kδ in Mature B-cell Malignancies.
Cooney JD; Lin AP; Jiang D; Wang L; Suhasini AN; Myers J; Qiu Z; Wölfler A; Sill H; Aguiar RCT
Clin Cancer Res; 2018 Mar; 24(5):1103-1113. PubMed ID: 29246942
[No Abstract] [Full Text] [Related]
8. Rational combined targeting of phosphodiesterase 4B and SYK in DLBCL.
Kim SW; Rai D; McKeller MR; Aguiar RC
Blood; 2009 Jun; 113(24):6153-60. PubMed ID: 19369227
[TBL] [Abstract][Full Text] [Related]
9. Phosphodiesterase-4 inhibition augments human lung fibroblast vascular endothelial growth factor production induced by prostaglandin E2.
Ikari J; Michalski JM; Iwasawa S; Gunji Y; Nogel S; Park JH; Nelson AJ; Farid M; Wang X; Schulte N; Basma H; Toews ML; Feghali-Bostwick C; Tenor H; Liu X; Rennard SI
Am J Respir Cell Mol Biol; 2013 Oct; 49(4):571-81. PubMed ID: 23656623
[TBL] [Abstract][Full Text] [Related]
10. Regulation of PD-L1 expression is a novel facet of cyclic-AMP-mediated immunosuppression.
Sasi B; Ethiraj P; Myers J; Lin AP; Jiang S; Qiu Z; Holder KN; Aguiar RCT
Leukemia; 2021 Jul; 35(7):1990-2001. PubMed ID: 33299141
[TBL] [Abstract][Full Text] [Related]
11. PDE4 inhibition reduces neointima formation and inhibits VCAM-1 expression and histone methylation in an Epac-dependent manner.
Lehrke M; Kahles F; Makowska A; Tilstam PV; Diebold S; Marx J; Stöhr R; Hess K; Endorf EB; Bruemmer D; Marx N; Findeisen HM
J Mol Cell Cardiol; 2015 Apr; 81():23-33. PubMed ID: 25640159
[TBL] [Abstract][Full Text] [Related]
12. The unrecognized effects of phosphodiesterase 4 on epithelial cells in pulmonary inflammation.
Konrad FM; Bury A; Schick MA; Ngamsri KC; Reutershan J
PLoS One; 2015; 10(4):e0121725. PubMed ID: 25909327
[TBL] [Abstract][Full Text] [Related]
13. MicroRNA-124 regulates glucocorticoid sensitivity by targeting phosphodiesterase 4B in diffuse large B cell lymphoma.
Kim J; Jeong D; Nam J; Aung TN; Gim JA; Park KU; Kim SW
Gene; 2015 Mar; 558(1):173-80. PubMed ID: 25576220
[TBL] [Abstract][Full Text] [Related]
14. Cross-talk between PKA-Cβ and p65 mediates synergistic induction of PDE4B by roflumilast and NTHi.
Susuki-Miyata S; Miyata M; Lee BC; Xu H; Kai H; Yan C; Li JD
Proc Natl Acad Sci U S A; 2015 Apr; 112(14):E1800-9. PubMed ID: 25831493
[TBL] [Abstract][Full Text] [Related]
15. A macrophage-dominant PI3K isoform controls hypoxia-induced HIF1α and HIF2α stability and tumor growth, angiogenesis, and metastasis.
Joshi S; Singh AR; Zulcic M; Durden DL
Mol Cancer Res; 2014 Oct; 12(10):1520-31. PubMed ID: 25103499
[TBL] [Abstract][Full Text] [Related]
16. Phosphodiesterase 4 inhibitors have wide-ranging activity in B-cell malignancies.
Cooney JD; Aguiar RC
Blood; 2016 Dec; 128(25):2886-2890. PubMed ID: 27756749
[TBL] [Abstract][Full Text] [Related]
17. Roflumilast treatment inhibits lung carcinogenesis in benzo(a)pyrene-induced murine lung cancer model.
Yeo CD; Kim YA; Lee HY; Kim JW; Kim SJ; Lee SH; Kim YK
Eur J Pharmacol; 2017 Oct; 812():189-195. PubMed ID: 28684234
[TBL] [Abstract][Full Text] [Related]
18. Sensitivity to PI3K and AKT inhibitors is mediated by divergent molecular mechanisms in subtypes of DLBCL.
Erdmann T; Klener P; Lynch JT; Grau M; Vočková P; Molinsky J; Tuskova D; Hudson K; Polanska UM; Grondine M; Mayo M; Dai B; Pfeifer M; Erdmann K; Schwammbach D; Zapukhlyak M; Staiger AM; Ott G; Berdel WE; Davies BR; Cruzalegui F; Trneny M; Lenz P; Barry ST; Lenz G
Blood; 2017 Jul; 130(3):310-322. PubMed ID: 28202458
[TBL] [Abstract][Full Text] [Related]
19. Safety and Pharmacodynamics of the PDE4 Inhibitor Roflumilast in Advanced B-cell Malignancies.
Kelly K; Mejia A; Suhasini AN; Lin AP; Kuhn J; Karnad AB; Weitman S; Aguiar RC
Clin Cancer Res; 2017 Mar; 23(5):1186-1192. PubMed ID: 27542768
[No Abstract] [Full Text] [Related]
20. PI3K/AKT and Mdm2 activation are associated with inhibitory effect of cAMP increasing agents on DNA damage-induced cell death in human pre-B NALM-6 cells.
Ghorbani A; Jeddi-Tehrani M; Saidpour A; Safa M; Bayat AA; Zand H
Arch Biochem Biophys; 2015 Jan; 566():58-66. PubMed ID: 25524737
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
